Apellis Pharmaceuticals Inc’s recently made public that its VP/Chief Accounting Officer Chopas James George unloaded Company’s shares for reported $4543.0 on Mar 17 ’25. In the deal valued at $24.82 per share,183 shares were sold. As a result of this transaction, Chopas James George now holds 47,955 shares worth roughly $1.17 million.
Then, Chopas James George bought 183 shares, generating $4,543 in total proceeds.
Before that, Watson David O. sold 5,569 shares. Apellis Pharmaceuticals Inc shares valued at $139,789 were divested by the General Counsel at a price of $25.10 per share. As a result of the transaction, Watson David O. now holds 138,730 shares, worth roughly $3.39 million.
Goldman downgraded its Apellis Pharmaceuticals Inc [APLS] rating to a Neutral from a a Buy in a research note published recently. A number of analysts have revised their coverage, including Morgan Stanley’s analysts, who began to cover the stock in late November with a ‘”an Equal-weight”‘ rating. RBC Capital Mkts began covering APLS with “Sector perform” recommendation on October 25, 2024. William Blair started covering the stock on October 16, 2024. It rated APLS as “an Outperform”.
Price Performance Review of APLS
On Tuesday, Apellis Pharmaceuticals Inc [NASDAQ:APLS] saw its stock fall -2.79% to $24.41. Over the last five days, the stock has lost -4.35%. Apellis Pharmaceuticals Inc shares have fallen nearly -23.50% since the year began. Nevertheless, the stocks have fallen -56.78% over the past one year. While a 52-week high of $59.91 was reached on 01/07/25, a 52-week low of $23.77 was recorded on 03/04/25. SMA at 50 days reached $28.18, while 200 days put it at $32.94.
Levels Of Support And Resistance For APLS Stock
The 24-hour chart illustrates a support level at 24.01, which if violated will result in even more drops to 23.61. On the upside, there is a resistance level at 24.92. A further resistance level may holdings at 25.43. The Relative Strength Index (RSI) on the 14-day chart is 36.76, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.35, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 83.02%. Stochastics %K at 22.67% indicates the stock is a holding.
How much short interest is there in Apellis Pharmaceuticals Inc?
A steep rise in short interest was recorded in Apellis Pharmaceuticals Inc stocks on 2025-02-28, growing by 3.76 million shares to a total of 20.82 million shares. Yahoo Finance data shows the prior-month short interest on 2025-01-31 was 17.06 million shares. There was a rise of 18.06%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on October 16, 2024 when Scotiabank began covering the stock and recommended ‘”a Sector outperform”‘ rating .
